Breast Cancer,HER2+ Phase 3 PRECIOUS Study: Pertuzumab Retreatment Benefits for HER2+ Cancer Patients Mar 28, 2023
Breast Cancer,HER2- Comparison of PAL + FUL vs. CAPE in the GEICAM/2013-02 (PEARL) Phase 3 Trial Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Patient Evaluation of Atezolizumab Added to Standard Treatment of PSROC Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Rucaparib as Second-Line Therapy in Advanced Ovarian Cancer: Efficacy and Safety Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Pros in the Mirasol and Forward I Trial on the Effect of MIRV in the Treatment of PROC Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Olaparib vs. Non-Platinum Chemotherapy for PSROC with BRCA1/2 Mutations Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Maintenance Olaparib in PSROC: Safety and Efficacy Regardless of BRCA Status Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Viability of Rucaparib for Recurring Ovarian Cancer: A Study Mar 28, 2023
